Morphic (NASDAQ:MORF – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.19), Zacks reports.
Morphic Stock Down 0.1 %
Shares of MORF stock traded down $0.06 during trading hours on Friday, reaching $56.55. 1,406,891 shares of the company’s stock were exchanged, compared to its average volume of 5,416,917. Morphic has a fifty-two week low of $19.34 and a fifty-two week high of $62.08. The stock has a market capitalization of $2.83 billion, a P/E ratio of -16.16 and a beta of 1.50. The business has a fifty day moving average price of $37.97 and a 200-day moving average price of $34.28.
Insider Transactions at Morphic
In other news, CFO Marc Schegerin sold 43,936 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $55.80, for a total transaction of $2,451,628.80. Following the completion of the transaction, the chief financial officer now directly owns 37,907 shares in the company, valued at $2,115,210.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Marc Schegerin sold 43,936 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $55.80, for a total transaction of $2,451,628.80. Following the completion of the transaction, the chief financial officer now directly owns 37,907 shares in the company, valued at $2,115,210.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel William Devaul sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $55.79, for a total value of $557,900.00. Following the transaction, the general counsel now owns 23,029 shares of the company’s stock, valued at $1,284,787.91. The disclosure for this sale can be found here. Insiders sold a total of 125,790 shares of company stock worth $7,018,566 over the last three months. 25.60% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
View Our Latest Analysis on Morphic
About Morphic
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.
Featured Articles
- Five stocks we like better than Morphic
- The 3 Best Retail Stocks to Shop for in August
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why Call Options Volume for These 2 Stocks Spiked Together
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.